Section Arrow
PDSB.NASDAQ
- PDS Biotechnology Corp
(Financial Status)
Quotes are at least 15-min delayed:2026/04/02 06:06 EDT
Pre Market
Last
 --
-- (--)
Bid
0.5665
Ask
0.6063
High -- 
Low -- 
Volume -- 
Regular Hours (Closed)
Last
 0.6063
+0.0013 (+0.21%)
Day High 
0.6132 
Prev. Close
0.605 
1-M High
0.734899 
Volume 
128.59K 
Bid
0.5665
Ask
0.6063
Day Low
0.575 
Open
0.6 
1-M Low
0.5068 
Market Cap 
33.11M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 0.59 
20-SMA 0.63 
50-SMA 0.71 
52-W High 1.915 
52-W Low 0.5068 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.81/-0.82
Enterprise Value
42.37M
Balance Sheet
Book Value Per Share
0.17
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
CYCNCyclerion Therapeutics6.38+4.83+311.61%-- 
Pre Market 5.44 -0.94 -14.73%
ELABPmgc Holdings Inc14+8.01+133.72%0PE
Pre Market 4.36 -9.64 -68.86%
IOBTIO Biotech0.0437-0.015-25.55%-- 
Pre Market 0.043 -0.0007 -1.60%
APLSApellis Pharmaceuticals40.39+0.16+0.40%224.11PE
Pre Market 40.3373 -0.0527 -0.13%
GERNGeron Corp1.66+0.17+11.41%-- 
Pre Market 1.62 -0.04 -2.41%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.